Effective Administration of Rituximab in Anti-MDA5 Antibody-Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review.
Yuka OgawaDai KishidaYasuhiro ShimojimaKoichi HayashiYoshiki SekijimaPublished in: Case reports in rheumatology (2017)
We describe the case of a 48-year-old man with dermatomyositis (DM) who demonstrated rapidly progressive interstitial lung disease (RP-ILD) and refractory cutaneous involvement together with high levels of anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5-Ab). Even after combination immunosuppressive therapy including a corticosteroid, cyclosporine A, and intravenous cyclophosphamide, his respiratory insufficiency and cutaneous involvement progressively worsened. However, the administration of rituximab (RTX) resulted in clinical remission as well as a visible reduction in anti-MDA5-Ab levels, suggesting that RTX could be a useful remedy in cases refractory to conventional immunosuppressive agents, especially those of RP-ILD related to anti-MDA5-Ab-positive DM.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- breast cancer cells
- multiple sclerosis
- disease activity
- low dose
- gene expression
- type diabetes
- stem cells
- high dose
- glycemic control
- systemic lupus erythematosus
- genome wide
- cell proliferation
- hodgkin lymphoma
- signaling pathway
- skeletal muscle
- weight loss
- insulin resistance
- smoking cessation
- transcription factor
- pi k akt
- ulcerative colitis
- replacement therapy